Cagrilintide 5 mg Research Peptide Vial

Main Title

Cagrilintide 5 mg — Long-Acting Amylin & Calcitonin Receptor Agonist for Metabolic & Weight Management Research

Full Description

Cagrilintide is a synthetic long-acting acylated analog of human amylin (IAPP). It functions as a dual amylin receptor (AMYR) and calcitonin receptor (CTR) agonist. It is extensively investigated in preclinical and clinical research for its potent effects on satiety, gastric emptying, and energy balance, particularly in models of obesity and metabolic dysfunction, often studied in combination with GLP-1 receptor agonists such as semaglutide.

What It Is

• Class: Long-acting amylin/calcitonin receptor agonist (DACRA)

• Concept: Mimics and prolongs the actions of endogenous amylin to enhance satiety signaling, slow gastric emptying, and support body weight regulation via central and peripheral pathways.

• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Amylin & Calcitonin Receptor Activation

• Binds with high affinity to amylin receptors (AMY1R, AMY2R, AMY3R) and calcitonin receptors (CTR), activating Gs-coupled cAMP signaling.

• Modulates brainstem and hypothalamic circuits involved in appetite suppression and energy homeostasis.

Gastrointestinal & Satiety Effects

• Delays gastric emptying and promotes feelings of fullness, reducing caloric intake in metabolic models.

• Synergizes with GLP-1 pathways to enhance weight loss and glycemic control.

Metabolic Regulation

• Investigated for effects on glucagon secretion, lipid metabolism, and preservation of lean mass during weight reduction.

Selected Research Highlights

• Weight Management: Produced robust, dose-dependent reductions in body weight and fat mass in preclinical obesity models.

• Combination with Semaglutide (CagriSema): Extensively investigated in combination with semaglutide, demonstrating synergistic and superior effects on body weight reduction, appetite suppression, and cardiometabolic parameters compared to either agent alone in relevant research models.

• Satiety & Food Intake: Demonstrated strong suppression of appetite and caloric intake via central amylin signaling pathways.

• Glycemic Control: Studied for improvements in fasting glucose and insulin sensitivity in type 2 diabetes models.

• Long-Acting Profile: Engineered with fatty acid acylation for prolonged pharmacokinetics suitable for once-weekly dosing in research settings.

Chemical & Handling Information

• Type: Synthetic acylated amylin analog

• Key Modifications: N-terminal lipidation (C20 fatty acid), stabilizing mutations

• Appearance: White to off-white lyophilized powder

Specifications

• Peptide: Cagrilintide

• Amount: 5 mg per vial

• Form: Lyophilized powder

• Purity: ≥99% (HPLC) – Certificate of Analysis available per lot

• Packaging: Sealed vials suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place protected from light.

• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability according to laboratory SOPs.

• After reconstitution: Store at 2–8 °C for short-term use.

• Long-term storage: Aliquot and freeze at –20 °C or below. Avoid repeated freeze-thaw cycles.